Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1981 1
1983 2
1984 3
1985 1
1986 4
1987 2
1988 1
1989 4
1990 3
1991 2
1992 2
1993 3
1994 2
1996 6
1997 4
1998 2
1999 6
2000 4
2001 7
2002 5
2003 6
2004 10
2005 7
2006 10
2007 14
2008 16
2009 15
2010 6
2011 9
2012 12
2013 14
2014 12
2015 18
2016 20
2017 27
2018 23
2019 23
2020 37
2021 35
2022 45
2023 54
2024 56
2025 49

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

527 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Basta, 5BAuthor
Page 1
Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands.
Bels JLM, Thiessen S, van Gassel RJJ, Beishuizen A, De Bie Dekker A, Fraipont V, Lamote S, Ledoux D, Scheeren C, De Waele E, van Zanten ARH, Bormans-Russell L, van Bussel BCT, Dictus MMJ, Fivez T, Harks I, van der Horst ICC, Jonckheer J, Marechal H, Massion PB, Meex I, Paulus MC, Rinket M, van Santen S, Tartaglia K, Deane AM, Demuydt F, Puthucheary Z, Vloet LCM, Weijs PJM, van Kuijk SMJ, van de Poll MCG, Mesotten D; PRECISe study team. Bels JLM, et al. Lancet. 2024 Aug 17;404(10453):659-669. doi: 10.1016/S0140-6736(24)01304-7. Lancet. 2024. PMID: 39153816 Free article. Clinical Trial.
The primary outcome was EuroQoL 5-Dimension 5-level (EQ-5D-5L) health utility score at 30 days, 90 days, and 180 days after randomisation, adjusted for baseline EQ-5D-5L health utility score. ...Regarding safety outcomes, the probability of mortality during the enti …
The primary outcome was EuroQoL 5-Dimension 5-level (EQ-5D-5L) health utility score at 30 days, 90 days, and 180 days after randomisa …
Vegan and Omnivorous High Protein Diets Support Comparable Daily Myofibrillar Protein Synthesis Rates and Skeletal Muscle Hypertrophy in Young Adults.
Monteyne AJ, Coelho MOC, Murton AJ, Abdelrahman DR, Blackwell JR, Koscien CP, Knapp KM, Fulford J, Finnigan TJA, Dirks ML, Stephens FB, Wall BT. Monteyne AJ, et al. J Nutr. 2023 Jun;153(6):1680-1695. doi: 10.1016/j.tjnut.2023.02.023. Epub 2023 Feb 22. J Nutr. 2023. PMID: 36822394 Free PMC article. Clinical Trial.
METHODS: In Phase 1, 16 healthy young adults (m = 8, f = 8; age: 23 1 y; BMI: 23 1 kg/m(2)) completed a 3-d dietary intervention (high protein, 1.8 g.kg bm(-1).d(-1)) where protein was derived from omnivorous (OMNI1; n = 8) or exclusively non-animal (VEG1; n = 8) so …
METHODS: In Phase 1, 16 healthy young adults (m = 8, f = 8; age: 23 1 y; BMI: 23 1 kg/m(2)) completed a 3-d dietary interventi …
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Aldred J, et al. Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26. Neurol Ther. 2023. PMID: 37632656 Free PMC article.
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's …
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Mov …
[Asthenic post-COVID syndrome].
Khaibullina DK, Maksimov YN. Khaibullina DK, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(3):61-69. doi: 10.17116/jnevro202312303161. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 36946399 Russian.
Malkova, a questionnaire for the quality of life (EQ-5D), a questionnaire for identifying signs of autonomic disorders (Vayne A.M.). The patient's condition was monitored during follow-up visits 2 weeks, 1 month after the start of treatment and 1 month after the end …
Malkova, a questionnaire for the quality of life (EQ-5D), a questionnaire for identifying signs of autonomic disorders (Vayne A.M …
Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study.
Galván Ruiz M, Fernández de Sanmamed Girón M, Del Val Groba Marco M, Rojo Jorge L, Peña Saavedra C, Martín Bou E, Andrade Guerra R, Caballero Dorta E, García Quintana A. Galván Ruiz M, et al. ESC Heart Fail. 2024 Dec;11(6):4222-4230. doi: 10.1002/ehf2.15032. Epub 2024 Aug 18. ESC Heart Fail. 2024. PMID: 39155141 Free PMC article.

During follow-up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to 22.4% and 75.5% at study end; P < 0.001), as did the EuroQol-5D (EQ-5D) and visual analogue scale (VAS) scores (from

…
During follow-up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to …
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.
Strand V, Kalunian KC, Lee KW, Seo C, Abreu G, Tummala R, Al-Mossawi H, Duncan EA, Lindholm C. Strand V, et al. Lancet Rheumatol. 2025 Jul;7(7):e485-e494. doi: 10.1016/S2665-9913(25)00022-0. Epub 2025 May 2. Lancet Rheumatol. 2025. PMID: 40324450 Clinical Trial.
Exploratory endpoints were changes from baseline in patient-reported outcomes (Short Form-36 version 2 acute recall [SF-36v2 (acute)], Patient Global Assessment of disease activity, EuroQoL 5 Dimensions-5 Levels [EQ-5D-5L], and Work Productivity and Activity Impairment-Lup …
Exploratory endpoints were changes from baseline in patient-reported outcomes (Short Form-36 version 2 acute recall [SF-36v2 (acute)], Patie …
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.
van de Bovenkamp AA, Geurkink KTJ, Oosterveer FTP, de Man FS, Kok WEM, Bronzwaer PNA, Allaart CP, Nederveen AJ, van Rossum AC, Bakermans AJ, Handoko ML. van de Bovenkamp AA, et al. ESC Heart Fail. 2023 Oct;10(5):2998-3010. doi: 10.1002/ehf2.14418. Epub 2023 Aug 2. ESC Heart Fail. 2023. PMID: 37530098 Free PMC article. Clinical Trial.
The study included 25 patients (10/15 males/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg/m(2) ); with the diagnosis of HFpEF confirmed with (exercise) right heart catheterization either before or during the trial. ...There was no ch …
The study included 25 patients (10/15 males/females; mean (standard deviation) age, 66 (10) years; body mass index, 29.8 (4.5) kg/m(2 …
Lanthanide Photocatalysis.
Qiao Y, Schelter EJ. Qiao Y, et al. Acc Chem Res. 2018 Nov 20;51(11):2926-2936. doi: 10.1021/acs.accounts.8b00336. Epub 2018 Oct 18. Acc Chem Res. 2018. PMID: 30335356
Among the lanthanides, we have focused on cerium because of the doublet to doublet 4f 5d excitation and emission, which affords good conservation of energy without losses through spin-state changes, as well as a large natural abundance of that element. ...This complex is a …
Among the lanthanides, we have focused on cerium because of the doublet to doublet 4f 5d excitation and emission, which affords good …
Evaluation of the accuracy of digital impressions with different scanning strategies: An in vitro study.
Ortensi L, La Rosa GRM, Ciletta S, Grande F, Pedullà E. Ortensi L, et al. J Dent. 2024 Dec;151:105433. doi: 10.1016/j.jdent.2024.105433. Epub 2024 Oct 28. J Dent. 2024. PMID: 39490607 Free article.
RESULTS: No significant differences in trueness were found among strategies (S1: 9.98 m, S2: 11.93 m, S3: 8.84 m; p = .388) in Trios 3 and iTero Element 5D (S1: 12.24 m, S2: 11.53 m, S3: 10.71 m; p = p = .279). ...Trios 3 had highe …
RESULTS: No significant differences in trueness were found among strategies (S1: 9.98 m, S2: 11.93 m, S3: 8.84 m; p = . …
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Waterhouse DM, et al. Lung Cancer. 2024 Oct;196:107921. doi: 10.1016/j.lungcan.2024.107921. Epub 2024 Aug 6. Lung Cancer. 2024. PMID: 39303400 Free article. Clinical Trial.
METHODS: In CodeBreaK 200, 345 patients who had progressed after prior therapy received sotorasib (960 mg orally daily) or docetaxel (75 mg/m(2) intravenously every 3 weeks). Validated questionnaires captured patients' perception of their QOL and symptom burden for key sec …
METHODS: In CodeBreaK 200, 345 patients who had progressed after prior therapy received sotorasib (960 mg orally daily) or docetaxel (75 mg/ …
527 results